Ece Genç
Research Subjects
Ece Genç has a total of 123 co-authors. Here are the top co-authors by number of shared publications:
U. Havemann
Department of Biochemical Pharmacology, Max Planck Institute for Experimental Medicine, D-3400 Göttingen, FRG
3 shared publicationsH. Koyuncuoĝlu
Istanbul University
2 shared publicationsH. Saĝduyu
Istanbul University
2 shared publicationsK. Kuschinsky
Max Planck Institute for Experimental Medicine
2 shared publicationsL EROGLU
2 shared publicationsL. Eroĝlu
Istanbul University
2 shared publications
Latest Publications
- 20 January 2024
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 92
Development and evaluation of 3D-printed ocular insert containing liposomal moxifloxacin
- 20 January 2024
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 92
Development and evaluation of 3D-printed ocular insert containing liposomal moxifloxacin
- Open Access
- 24 May 2022
- Published by Anadolu Klinigi Tip Bilimleri Dergisi in Anadolu Kliniği Tıp Bilimleri Dergisi
- Vol. 27 (2) , 194-203
Anti-apoptotic effects of valproic acid treatment on dopaminergic neuronal loss in a 6-hydroxydopamine model of Parkinson’s disease in rats
Aim: Parkinson’s disease (PD) is characterized by the progressive loss of dopaminergic neurons resulting in deterioration of motor activity in patients. Currently, available therapies including Levodopa (L-DOPA) are more geared toward the treatment of symptoms. Therefore, developing effective neuroprotective therapies is needed. Valproic acid (VPA) has shown potent neuroprotective effects on dopamine (DA) neurons in various brain regions. The aim of this study is to investigate whether VPA attenuates the neuronal loss when co-treated with L-DOPA in a 6-hydroxydopamine (6-OHDA) induced PD model in rats.Methods: Male Wistar Albino rats received intranigral injection of 6-OHDA unilaterally. Twelve days later rats received either saline, L-DOPA, VPA, or L-DOPA+ VPA for 9 days. To determine whether rats had dopaminergic neuronal loss apomorphine-induced rotation test was used. Immunohistochemical analyses were performed in the Substantia Nigra pars compacta (SNpc) by measuring the tyrosine hydroxylase (TH) positive neurons and the apoptotic neurons.Results: 6-OHDA injection showed clinically impairment of the motor function with histologically significant damage to the dopaminergic neurons. VPA administration combined with L- DOPA protected neurons in SNpc by increasing the TH positive neurons and by decreasing the apoptotic neurons. L-DOPA given as a monotherapy, on the other hand, was ineffective on these parameters.Conclusion: Our experiments demonstrated that VPA had a neuroprotective effect when used with L-DOPA in the PD rat model.
- 24 May 2022
- Published by Anadolu Klinigi Tip Bilimleri Dergisi in Anadolu Kliniği Tıp Bilimleri Dergisi
- Vol. 27 (2) , 194-203
Open AccessAnti-apoptotic effects of valproic acid treatment on dopaminergic neuronal loss in a 6-hydroxydopamine model of Parkinson’s disease in rats
Aim: Parkinson’s disease (PD) is characterized by the progressive loss of dopaminergic neurons resulting in deterioration of motor activity in patients. Currently, available therapies including Levodopa (L-DOPA) are more geared toward the treatment of symptoms. Therefore, developing effective neuroprotective therapies is needed. Valproic acid (VPA) has shown potent neuroprotective effects on dopamine (DA) neurons in various brain regions. The aim of this study is to investigate whether VPA attenuates the neuronal loss when co-treated with L-DOPA in a 6-hydroxydopamine (6-OHDA) induced PD model in rats.Methods: Male Wistar Albino rats received intranigral injection of 6-OHDA unilaterally. Twelve days later rats received either saline, L-DOPA, VPA, or L-DOPA+ VPA for 9 days. To determine whether rats had dopaminergic neuronal loss apomorphine-induced rotation test was used. Immunohistochemical analyses were performed in the Substantia Nigra pars compacta (SNpc) by measuring the tyrosine hydroxylase (TH) positive neurons and the apoptotic neurons.Results: 6-OHDA injection showed clinically impairment of the motor function with histologically significant damage to the dopaminergic neurons. VPA administration combined with L- DOPA protected neurons in SNpc by increasing the TH positive neurons and by decreasing the apoptotic neurons. L-DOPA given as a monotherapy, on the other hand, was ineffective on these parameters.Conclusion: Our experiments demonstrated that VPA had a neuroprotective effect when used with L-DOPA in the PD rat model.
- 2 December 2018
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 105 (6) , 1477-1491
Effect of CYP4F2,VKORC1, and CYP2C9 in Influencing Coumarin Dose: A Single‐Patient Data Meta‐Analysis in More Than 15,000 Individuals
The cytochrome P450 (CYP)4F2 gene is known to influence mean coumarin dose. The aim of the present study was to undertake a meta‐analysis at the individual patients level to capture the possible effect of ethnicity, gene—gene interaction, or other drugs on the association and to verify if inclusion of CYP4F2*3 variant into dosing algorithms improves the prediction of mean coumarin dose. We asked the authors of our previous meta‐analysis (30 articles) and of 38 new articles retrieved by a systematic review to send us individual patients’ data. The final collection consists of 15,754 patients split into a derivation and validation cohort. The CYP4F2*3 polymorphism was consistently associated with an increase in mean coumarin dose (+9% (95% confidence interval (CI) 7–10%), with a higher effect in women, in patients taking acenocoumarol, and in white patients. The inclusion of the CYP4F2*3 in dosing algorithms slightly improved the prediction of stable coumarin dose. New pharmacogenetic equations potentially useful for clinical practice were derived.
- 2 December 2018
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 105 (6) , 1477-1491
Effect of CYP4F2,VKORC1, and CYP2C9 in Influencing Coumarin Dose: A Single‐Patient Data Meta‐Analysis in More Than 15,000 Individuals
The cytochrome P450 (CYP)4F2 gene is known to influence mean coumarin dose. The aim of the present study was to undertake a meta‐analysis at the individual patients level to capture the possible effect of ethnicity, gene—gene interaction, or other drugs on the association and to verify if inclusion of CYP4F2*3 variant into dosing algorithms improves the prediction of mean coumarin dose. We asked the authors of our previous meta‐analysis (30 articles) and of 38 new articles retrieved by a systematic review to send us individual patients’ data. The final collection consists of 15,754 patients split into a derivation and validation cohort. The CYP4F2*3 polymorphism was consistently associated with an increase in mean coumarin dose (+9% (95% confidence interval (CI) 7–10%), with a higher effect in women, in patients taking acenocoumarol, and in white patients. The inclusion of the CYP4F2*3 in dosing algorithms slightly improved the prediction of stable coumarin dose. New pharmacogenetic equations potentially useful for clinical practice were derived.
- 1 December 2009
- Published by Bentham Science Publishers Ltd. in Current Pharmacogenomics and Personalized Medicine
- Vol. 7 (4) , 297-301
Personalized and Predictive Medicine in Turkey: A Symposium Report of the Istanbul Working Group on Personalized Medicine, Istanbul, Turkey, September 10-12, 2009
Pharmacogenetics has its roots in the 1950s with pioneering studies of monogenic variations in drug metabolism and pharmacokinetics. With the availability of high-throughput genomics technologies and the completion of the Human Genome Project in 2003, we are now in the postgenomics era. This transition is increasingly marked with study of polygenic and multifactorial traits such as common complex human diseases as well as pharmacodynamic differences among populations. Changes that emerge from postgenomics medicine are not, however, limited to seismic shifts in scale and scope of pharmacogenetics research. Importantly, many low- and middle-income countries (LMICs) of the South, Asia-Pacific, Eastern Mediterranean and the Middle-East are becoming notable contributors with rapid globalization of science and increasing access to genomics technologies. This brings about, in parallel, an acute demand for regional capacity building in LMICs so that the future evaluation and implementation of postgenomics technologies in personalized medicine take place in an integrated, sustainable and equitable manner. With this overarching vision, we herein report the founding of the Istanbul Working Group in Personalized Medicine (IWG-PM, represented by the authors of this report) that was inaugurated as a component of the 2nd Symposium on Personalized and Predictive Medicine held in Istanbul, sponsored by the Yeditepe University, and the Turkish Scientific and Technological Research Council (TUBYTAK) (10-12 September, 2009). While highlighting the applications of personalized medicine in oncology, psychiatry, nutrition, infectious diseases, occupational health, genetic testing and systems biology, the symposium also raised challenging questions in the context of LMICs. How can we best evaluate the promises, intended and unintended impacts of personalized medicine and enabling technologies in the context of Turkey, and the LMICs more generally? IWG-PM is a small but significant and necessary step to initiate regional capacity building in Turkey. We trust that the IWG-PM initiative may also provide a constructive example to further develop capacity in other LMICs in the Eastern Mediterranean region.
- 1 December 2009
- Published by Bentham Science Publishers Ltd. in Current Pharmacogenomics and Personalized Medicine
- Vol. 7 (4) , 297-301
Personalized and Predictive Medicine in Turkey: A Symposium Report of the Istanbul Working Group on Personalized Medicine, Istanbul, Turkey, September 10-12, 2009
Pharmacogenetics has its roots in the 1950s with pioneering studies of monogenic variations in drug metabolism and pharmacokinetics. With the availability of high-throughput genomics technologies and the completion of the Human Genome Project in 2003, we are now in the postgenomics era. This transition is increasingly marked with study of polygenic and multifactorial traits such as common complex human diseases as well as pharmacodynamic differences among populations. Changes that emerge from postgenomics medicine are not, however, limited to seismic shifts in scale and scope of pharmacogenetics research. Importantly, many low- and middle-income countries (LMICs) of the South, Asia-Pacific, Eastern Mediterranean and the Middle-East are becoming notable contributors with rapid globalization of science and increasing access to genomics technologies. This brings about, in parallel, an acute demand for regional capacity building in LMICs so that the future evaluation and implementation of postgenomics technologies in personalized medicine take place in an integrated, sustainable and equitable manner. With this overarching vision, we herein report the founding of the Istanbul Working Group in Personalized Medicine (IWG-PM, represented by the authors of this report) that was inaugurated as a component of the 2nd Symposium on Personalized and Predictive Medicine held in Istanbul, sponsored by the Yeditepe University, and the Turkish Scientific and Technological Research Council (TUBYTAK) (10-12 September, 2009). While highlighting the applications of personalized medicine in oncology, psychiatry, nutrition, infectious diseases, occupational health, genetic testing and systems biology, the symposium also raised challenging questions in the context of LMICs. How can we best evaluate the promises, intended and unintended impacts of personalized medicine and enabling technologies in the context of Turkey, and the LMICs more generally? IWG-PM is a small but significant and necessary step to initiate regional capacity building in Turkey. We trust that the IWG-PM initiative may also provide a constructive example to further develop capacity in other LMICs in the Eastern Mediterranean region.
- 1 December 1992
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 2 (12) , 1535-1540
UK-73,093: A non-peptide neurotensin receptor antagonist
- 1 December 1992
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 2 (12) , 1535-1540
UK-73,093: A non-peptide neurotensin receptor antagonist
- 1 January 1987
- Vol. 39 (1) , 41-45
NALOXONE AND LITHIUM INTERACTION ON THE LEVELS OF HOMOVANILLIC-ACID IN THE RAT-BRAIN
The effects of long term (10 days) treatment of lithium and naloxone on HVA levels of striatum, hypothalamus and frontal cortex in rats were investigated. Lithium (400 mg/l in drinking water) itself had no effect on HVA levels of any region. Naloxone (2 mg/kg) treatment caused significant increases in the levels of HVA in hypothalamus and striatum and lithium cotreatment prevented the effect of naloxone. Neither of those were observed in the frontal cortical region.
- 1 January 1987
- Vol. 39 (1) , 41-45
NALOXONE AND LITHIUM INTERACTION ON THE LEVELS OF HOMOVANILLIC-ACID IN THE RAT-BRAIN
The effects of long term (10 days) treatment of lithium and naloxone on HVA levels of striatum, hypothalamus and frontal cortex in rats were investigated. Lithium (400 mg/l in drinking water) itself had no effect on HVA levels of any region. Naloxone (2 mg/kg) treatment caused significant increases in the levels of HVA in hypothalamus and striatum and lithium cotreatment prevented the effect of naloxone. Neither of those were observed in the frontal cortical region.
- 1 January 1984
- Vol. 36 (1) , 1-6
EFFECT OF NALOXONE ON APOMORPHINE-INDUCED CHANGES IN LOCOMOTOR-ACTIVITY OF STRESS-EXPOSED RATS
Acute and subacute effects of naloxone (10 mg/kg), apomorphine (0.125 mg/kg; 5 mg/kg) and stressful stimuli (immobilization, cold and sound) on locomotor activity were examined. In both acute and subacute (8 days) treatments, the lower dose of apomorphine decreased locomotor activity and the higher dose of apomorphine increased it. In the acute treatment, naloxone enhanced significantly the depressant effect of the lower dose of apomorphine on locomotor activity. Stress seemed to have no effect on apomorphine induced changes in locomotor activity of rats either in acute or in subacute treatment.
- 1 January 1984
- Vol. 36 (1) , 1-6
EFFECT OF NALOXONE ON APOMORPHINE-INDUCED CHANGES IN LOCOMOTOR-ACTIVITY OF STRESS-EXPOSED RATS
Acute and subacute effects of naloxone (10 mg/kg), apomorphine (0.125 mg/kg; 5 mg/kg) and stressful stimuli (immobilization, cold and sound) on locomotor activity were examined. In both acute and subacute (8 days) treatments, the lower dose of apomorphine decreased locomotor activity and the higher dose of apomorphine increased it. In the acute treatment, naloxone enhanced significantly the depressant effect of the lower dose of apomorphine on locomotor activity. Stress seemed to have no effect on apomorphine induced changes in locomotor activity of rats either in acute or in subacute treatment.
- 1 April 1983
- Published by Elsevier in Neuropharmacology
- Vol. 22 (4) , 471-476
Motility, rigidity and turnover of dopamine in the striatum after administration of morphine to rats: A re-evaluation of their mechanisms
- 1 April 1983
- Published by Elsevier in Neuropharmacology
- Vol. 22 (4) , 471-476
Motility, rigidity and turnover of dopamine in the striatum after administration of morphine to rats: A re-evaluation of their mechanisms
- 1 August 1981
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 317 (1) , 44-50
Effects of striatal lesions with kainic acid on morphine-induced ?catatonia? and increase of striatal dopamine turnover
The influence of striatal lesions (head of the caudate nucleus) with kainic acid on “catatonia” and on the increase of the dopamine metabolite DOPAC in the striatum after systemic morphine administration was measured in rats. These lesions strongly prevented the morphine-induced muscular rigidity, measured as activity in the electromyogram (EMG) of the gastrocnemius-soleus muscle of non-anesthesized animals. On the other hand, the decrease of locomotion (akinesia) measured using an Animex Activity Meter and an acitivity wheel, was not prevented or reduced. The lesions did not influence the inhibitory effect of morphine on the activation of flexor α-motoneurones, either. These results suggest that the head of the caudate nucleus plays an important role in mediating morphine rigidity, but not akinesia or inhibition of the activation of flexor α-motoneurones. Opioid-induced “catatonia” ought to be regarded as a mixture both of rigidity and of akinesia. Morphine led to a rapid decrease, followed by a slow increase of striatal DOPAC concentration. Lesions induced by kainic acid slightly inhibited the decrease and markedly enhanced the increase of DOPAC. Accordingly, an intact nigro-striato-nigral loop is not necessary for the increase of striatal dopamine turnover, observed after morphine administration. The different sites of action, which are likely to mediate all these effects of morphine, are discussed.
- 1 August 1981
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 317 (1) , 44-50
Effects of striatal lesions with kainic acid on morphine-induced ?catatonia? and increase of striatal dopamine turnover
The influence of striatal lesions (head of the caudate nucleus) with kainic acid on “catatonia” and on the increase of the dopamine metabolite DOPAC in the striatum after systemic morphine administration was measured in rats. These lesions strongly prevented the morphine-induced muscular rigidity, measured as activity in the electromyogram (EMG) of the gastrocnemius-soleus muscle of non-anesthesized animals. On the other hand, the decrease of locomotion (akinesia) measured using an Animex Activity Meter and an acitivity wheel, was not prevented or reduced. The lesions did not influence the inhibitory effect of morphine on the activation of flexor α-motoneurones, either. These results suggest that the head of the caudate nucleus plays an important role in mediating morphine rigidity, but not akinesia or inhibition of the activation of flexor α-motoneurones. Opioid-induced “catatonia” ought to be regarded as a mixture both of rigidity and of akinesia. Morphine led to a rapid decrease, followed by a slow increase of striatal DOPAC concentration. Lesions induced by kainic acid slightly inhibited the decrease and markedly enhanced the increase of DOPAC. Accordingly, an intact nigro-striato-nigral loop is not necessary for the increase of striatal dopamine turnover, observed after morphine administration. The different sites of action, which are likely to mediate all these effects of morphine, are discussed.
- 31 December 1980
- Published by Elsevier in Brain Research Bulletin
- Vol. 5, 891-896
Opioid actions on motility: Possible actions on GABA-ergic and dopaminergic neurons
- 31 December 1980
- Published by Elsevier in Brain Research Bulletin
- Vol. 5, 891-896
Opioid actions on motility: Possible actions on GABA-ergic and dopaminergic neurons